Ménière disease (MD) is a chronic inner ear disorder characterized by recurrent vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness. Diagnosis is clinical, and no validated peripheral biomarkers are available. Although endolymphatic hydrops is a hallmark, its poor correlation with symptom severity suggests broader systemic mechanisms.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for current clinical practice; this biomarker discovery study is exploratory and requires replication and validation before informing diagnosis or treatment of Ménière disease.
Identifying reliable biomarkers for Ménière disease could eventually enable objective diagnosis and targeted therapies for a condition currently managed by symptom control alone.
- 01High-throughput proteomics identified neurovascular (blood vessel/nerve) and immune system biomarkers in Ménière disease patients.
- 02Findings provide new clues about the biological mechanisms driving this poorly understood inner ear disorder.
- 03Published in Otology & Neurotology, a leading peer-reviewed ear surgery journal.
- 04Biomarkers may point toward future targets for drug development.
- 05Study is exploratory; clinical application of these biomarkers is not yet established.
Neurovascular and immune biomarkers identified through proteomics offer new insights into the pathophysiology of Ménière disease.
studypartially supported- PMID
- 42584982
- DOI
- 10.1097/MAO.0000000000004986.
- Journal
- Otology & Neurotology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients diagnosed with Ménière disease
- Intervention
- High-throughput proteomics analysis to identify neurovascular and immune biomarkers
Primary outcomes
Identification of neurovascular and immune protein biomarkers associated with Ménière disease; Characterisation of pathophysiological mechanisms in Ménière disease via proteomic profiles